Tepotinib is recommended, within its marketing authorisation, as an option for treating advanced non-small-cell lung cancer (NSCLC) with METex14 skipping alterations in adults, only if the company provides tepotinib according to the commercial arrangement.
Standard care for advanced METex14 skipping NSCLC is usually chemo-immunotherapy. People have different treatments depending on their PD‑L1 tumour proportion score and whether they have squamous or non-squamous NSCLC.
Clinical trial evidence suggests a clinical benefit for tepotinib. It has been indirectly compared with other treatments in 2 ways, but the results of both are uncertain.
Tepotinib meets NICE's criteria to be considered a life-extending drug at the end of life for people who have had previous treatment, but not for people who have not had previous treatment.
For both groups, the cost-effectiveness estimates are within the range NICE normally considers an acceptable use of NHS resources. So, tepotinib is recommended.